Licensed Bulk Medicines
key details
| Value | £42,317,737 |
|---|---|
| Status | planned |
| Category (CPV) | 33600000 |
| Region | Wales |
| OCID | ocds-h6vhtk-03d4f5 |
description
We are interested in buying the following list of products, in licensed bulk containers of up to the sizes noted below, to be available within a 5 year timeframe. We consider the availability in licensed bulk presentation to be a significant market advantage and are willing to consider entering contracts for supply with suppliers who can meet this presentation requirement for these products.
Estimated value in the Wales market of this list is £42,317,736.61 p/a at current prices.
The list is not exhaustive, and we are willing to consider other generic and biosimilar products if licensed bulk presentation can be offered.
Drug,Strength,Proposed Vial Size
ARSENIC TRIOXIDE,1mg/mL,
AZACITIDINE,25mg/mL,500mL
BEVACIZUMAB,25mg/mL,100mL - 250mL
BORTEZOMIB,2.5mg/mL,50mL
CALCIUM FOLINATE,10mg/mL,1000mL
CARBOPLATIN,10mg/mL,1000mL
CETUXIMAB,5mg/mL,250m – 500mL
CISPLATIN,1mg/mL,500mL - 1000mL
CYCLOPHOSPHAMIDE,20mg/mL,500mL
CYTARABINE,100mg/mL or 20mg/mL,250mL
DARATUMUMAB,20mg/mL,100mL – 250mL
DOCETAXEL,20mg/mL,250mL - 500mL
DOXORUBICIN,2mg/mL,1000mL
EPIRUBICIN,2mg/mL,1000mL
ETOPOSIDE,20mg/mL,500mL
FLUCLOXACILLIN,,3000mL
FLUOROURACIL,50mg/mL or 25mg /mL,250-500mL
INFLIXIMAB,10mg/mL,500mL - 1000mL
IRINOTECAN,20mg/mL,1000mL
NIVOLUMAB,10mg/mL,250mL
OXALIPLATIN,5mg/mL,500mL-1000mL
PACLITAXEL,6mg/mL,1000mL
PEMBROLIZUMAB,25mg/mL,100mL – 250mL
PEMETREXED,25mg/mL,100mL – 250mL
PIPERACILLIN & TAZOBACTAM,,3000mL
RITUXIMAB,10mg/mL,500mL
TOCILIZUMAB,20mg/mL,250mL
TRASTUZUMAB EMTANSINE,20mg/mL,100mL - 250mL
VEDOLIZUMAB,60mg/mL,250mL
VITLIPID N INFANT,N/A,250mL
Please inform us via the contact information above if you are able to provide these products.
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 9 Jun 2023 | Prior information notice (F01) | Earlier regulations | 016383-2023 |
more from Velindre NHS Trust, NHS Wales Shared Services Partnership — Procurement Services (on behalf of All Wales LHB's and Trusts)
- Aseptics Medicines (Including Cytotoxics) · £9,014,913 · 31 Jul 2025
- Unlicensed Medicines - Imports & Specials · 20 Jan 2025
- Aseptically Prepared Systemic Anti-Cancer Treatment (SACT) · 9 Aug 2024
- Generic Anti-Infective Drugs · £3,390,876 · 19 Mar 2024
- Lenalidomide · 9 Dec 2022
- Transitional Drugs · 11 Oct 2022
- Generic Drugs - Injections/Infusions · 3 Aug 2022
- Proprietary Drugs · 14 Jul 2022
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Find a Tender. Contact details for named individuals are not reproduced on this site.